Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor Mutations”

337 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 337 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06436144
What this trial is testing

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIB+1 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 93
Early research (Phase 1)Active Not RecruitingNCT04141644
What this trial is testing

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

Who this might be right for
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
University of Utah 24
Not applicableStudy completedNCT02285361
What this trial is testing

GIOTRIF rPMS in Korean Patients With NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 1,272
Testing effectiveness (Phase 2)UnknownNCT03720873
What this trial is testing

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

Who this might be right for
EGFR Gene Mutation
Fujian Cancer Hospital 90
Large-scale testing (Phase 3)Active Not RecruitingNCT05870319
What this trial is testing

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 376
Not applicableStudy completedNCT02777658
What this trial is testing

PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 169
Post-approval studies (Phase 4)Study completedNCT02514174
What this trial is testing

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Who this might be right for
Carcinoma, Non-Small-Cell LungErbB Receptors
Boehringer Ingelheim 25
Not applicableEnded earlyNCT02483416
What this trial is testing

Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 30
Not applicableNot Yet RecruitingNCT05698264
What this trial is testing

A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationImmune Checkpoint Inhibitor
Nir Peled 50
Large-scale testing (Phase 3)Study completedNCT02296125
What this trial is testing

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AstraZeneca 674
Testing effectiveness (Phase 2)UnknownNCT02274337
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 100
Not applicableUnknownNCT01697163
What this trial is testing

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Who this might be right for
NSCLC
Severance Hospital 155
Testing effectiveness (Phase 2)UnknownNCT05165355
What this trial is testing

Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma

Who this might be right for
NSCLCEGF-R Positive Non-Small Cell Lung Cancer
Tongji University 90
Large-scale testing (Phase 3)Study completedNCT00874419
What this trial is testing

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

Who this might be right for
Non-small Cell Lung Cancer
Tongji University 165
Not applicableStudy completedNCT00898924
What this trial is testing

Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Alliance for Clinical Trials in Oncology 60
Early research (Phase 1)Active Not RecruitingNCT06685718
What this trial is testing

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerLung CancerNSCLC+3 more
BeOne Medicines 33
Early research (Phase 1)UnknownNCT05504213
What this trial is testing

A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 224
Testing effectiveness (Phase 2)Looking for participantsNCT06222489
What this trial is testing

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

Who this might be right for
Non-Small Cell Lung CarcinomaAdvanced Non-Small Cell Squamous Lung CancerEGFR Gene Mutation
The Netherlands Cancer Institute 16
Early research (Phase 1)Study completedNCT02113813
What this trial is testing

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non-Small-Cell Lung Cancer (NSCLC)Epidermal Growth Factor Receptor Mutations
Astellas Pharma Global Development, Inc. 133
Large-scale testing (Phase 3)Looking for participantsNCT04853342
What this trial is testing

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Who this might be right for
Non-small Cell Lung Carcinoma
Allist Pharmaceuticals, Inc. 318
Load More Results